Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
NCT02038933
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
121
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma. Non-Hodgkin
Interventions
DRUG:
Nivolumab
Sponsor
Bristol-Myers Squibb